# ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction

Study · id `cardio:ct-nct04476173` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04476173](<https://clinicaltrials.gov/study/NCT04476173>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04476173

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04476173. Randomized; no masking; primary purpose treatment. Start 2020-06-01 (actual); primary completion 2024-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04476173, source copy `cardio:ctgov-nct04476173-2023-09-11`, retrieved 2026-10-26)
- Started: 2020-06-01 (actual) (ClinicalTrials.gov record NCT04476173, source copy `cardio:ctgov-nct04476173-2023-09-11`, retrieved 2026-10-26)
- Primary completion: 2024-06-30 (anticipated) (ClinicalTrials.gov record NCT04476173, source copy `cardio:ctgov-nct04476173-2023-09-11`, retrieved 2026-10-26)
- Completion: 2024-12-30 (anticipated) (ClinicalTrials.gov record NCT04476173, source copy `cardio:ctgov-nct04476173-2023-09-11`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT04476173, source copy `cardio:ctgov-nct04476173-2023-09-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04476173-2023-09-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction
- Acronym: ANEMON
- Condition: ST Elevation Myocardial Infarction
- Condition: Non ST Segment Elevation Acute Coronary Syndrome
- Intervention (Drug): Methoxyflurane - Penthrox
- Intervention (Drug): Morphine
- Lead sponsor: Collegium Medicum w Bydgoszczy
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Collegium Medicum w Bydgoszczy (`cardio:org-collegium-medicum-w-bydgoszczy`)

## Provenance

Content hash: 6d0cf74d01941e7edd344214e046c314c0cf01fb6acfde072f885f81ce119f18
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
